About this item:
432 Views | 191 Downloads
Author Notes:
Corresponding authors (RFS and FA) Tel.: +1-404-727-1414; rschina@emory.edu and famblar@emory.edu.
Dr. Schinazi is the Chairman and a major shareholder of Cocrystal Pharma, Inc.
Subjects:
Research Funding:
This work was supported in part by NIH grant 5P30-AI-50409 (CFAR).
Emory received no funding from Cocrystal Pharma, Inc. to perform this work and vice versa.
Keywords:
- Science & Technology
- Life Sciences & Biomedicine
- Physical Sciences
- Chemistry, Medicinal
- Chemistry, Organic
- Pharmacology & Pharmacy
- Chemistry
- Synthesis
- Nucleoside
- Prodrug
- Hepatitis C virus
- HUMAN-IMMUNODEFICIENCY-VIRUS
- HEPATITIS-C
- REPLICATION
- DISCOVERY
- CULTURE
Synthesis and anti-HCV activity of a series of beta-D-2 '-deoxy-2 '-dibromo nucleosides and their corresponding phosphoramidate prodrugs
Tools:
Abstract:
Several β-D-2′-deoxy-2′-substituted nucleoside analogs have displayed potent and selective anti-HCV activities and some of them have reached human clinical trials. In that regard, we report herein the synthesis of a series of 2′-deoxy,2′-dibromo substituted U, C, G and A nucleosides 10a–d and their corresponding phosphoramidate prodrugs 13a–d. The synthesized nucleosides 10a–d and prodrugs 13a–d were evaluated for their inhibitory activity against HCV as well as cellular toxicity. The results showed that the most potent compound was prodrug 13a, which exhibited micromolar inhibitory activity (EC50= 1.5 ± 0.8 µM) with no observed toxicity. In addition, molecular modeling and free energy perturbation calculations for the 5′-triphosphate formed from 13a and related 2′-modified nucleotides are discussed.
Copyright information:
© 2017 Elsevier Ltd
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
